In the REPAIR-T1D trial, a weak trend towards RBCF preservation was noted in a subgroup of patients with elevated glucagon-like peptide 1 (GLP-1) and gastrin concentrations, suggesting indirect effects of lansoprazole.
← all excerpts
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study.
1
—
—